Respiratory Failure

Categories: Infectious diseases, Rare diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Respiratory Failure

MalaCards integrated aliases for Respiratory Failure:

Name: Respiratory Failure 11 28 53 5 41 14 63 16 71 75 33
Acute Respiratory Failure 11 53 5 14 71 31 33
Chronic Respiratory Failure 11 53 71 31 33
Respiratory Insufficiency 28 5 71
Acute-on-Chronic Respiratory Failure 11 71
Acute and Chronic Respiratory Failure 11
Chronic Disease of Respiratory System 71
Respiratory Insufficiency/failure 11
Arf - [acute Respiratory Failure] 33
Acute Respiratory Insufficiency 33
Pulmonary Valve Insufficiency 71
Acute Pulmonary Insufficiency 33
Chronic Respiratory Disease 53
Chronic Respiration Failure 33
Respiratory Tract Diseases 71
Acute Respiration Failure 33
Respiration Disorders 71
Respiratory Disease 53
Pulmonary Failure 33
Lung Failure Nos 33


External Ids:

Disease Ontology 11 DOID:11162
ICD9CM 34 518.81
NCIt 49 C27043
SNOMED-CT 68 65710008
UMLS 71 C0034088 C0035204 C0035229 more

Summaries for Respiratory Failure

MedlinePlus: 41 What is respiratory failure? Respiratory failure is a condition in which your blood doesn't have enough oxygen or has too much carbon dioxide. Sometimes you can have both problems. When you breathe, your lungs take in oxygen. The oxygen passes into your blood, which carries it to your organs. Your organs, such as your heart and brain, need this oxygen-rich blood to work well. Another part of breathing is removing the carbon dioxide from the blood and breathing it out. Having too much carbon dioxide in your blood can harm your organs. What causes respiratory failure? Conditions that affect your breathing can cause respiratory failure. These conditions may affect the muscles, nerves, bones, or tissues that support breathing. Or they may affect the lungs directly. These conditions include: Diseases that affect the lungs, such as COPD (chronic obstructive pulmonary disease), cystic fibrosis, pneumonia, pulmonary embolism, and COVID-19 Conditions that affect the nerves and muscles that control breathing, such as amyotrophic lateral sclerosis (ALS), muscular dystrophy, spinal cord injuries, and stroke Problems with the spine, such as scoliosis (a curve in the spine). They can affect the bones and muscles used for breathing. Damage to the tissues and ribs around the lungs. An injury to the chest can cause this damage. Drug or alcohol overdose Inhalation injuries, such as from inhaling smoke (from fires) or harmful fumes What are the symptoms of respiratory failure? The symptoms of respiratory failure depend on the cause and the levels of oxygen and carbon dioxide in your blood. A low oxygen level in the blood can cause shortness of breath and air hunger (the feeling that you can't breathe in enough air). Your skin, lips, and fingernails may also have a bluish color. A high carbon dioxide level can cause rapid breathing and confusion. Some people who have respiratory failure may become very sleepy or lose consciousness. They also may have arrhythmia (irregular heartbeat). You may have these symptoms if your brain and heart are not getting enough oxygen. How is respiratory failure diagnosed? Your health care provider will diagnose respiratory failure based on: Your medical history A physical exam, which often includes Listening to your lungs to check for abnormal sounds Listening to your heart to check for arrhythmia Looking for a bluish color on your skin, lips, and fingernails Diagnostic tests, such as Pulse oximetry, a small sensor that uses a light to measure how much oxygen is in your blood. The sensor goes on the end of your finger or on your ear. Arterial blood gas test, a test that measures the oxygen and carbon dioxide levels in your blood. The blood sample is taken from an artery, usually in your wrist. Once you are diagnosed with respiratory failure, your provider will look for what is causing it. Tests for this often include a chest x-ray. If your provider thinks you may have arrhythmia because of the respiratory failure, you may have an EKG (electrocardiogram). This is simple, painless test that detects and records your heart's electrical activity. What are the treatments for respiratory failure? Treatment for respiratory failure depends on: Whether it is acute (short-term) or chronic (ongoing) How severe it is What is causing it Acute respiratory failure can be a medical emergency. You may need treatment in intensive care unit at a hospital. Chronic respiratory failure can often be treated at home. But if your chronic respiratory failure is severe, you might need treatment in a long-term care center. One of the main goals of treatment is to get oxygen to your lungs and other organs and remove carbon dioxide from your body. Another goal is to treat the cause of the condition. Treatments may include: Oxygen therapy, through a nasal cannula (two small plastic tubes that go in your nostrils) or through a mask that fits over your nose and mouth Tracheostomy, a surgically-made hole that goes through the front of your neck and into your windpipe. A breathing tube, also called a tracheostomy, or trach tube, is placed in the hole to help you breathe. Ventilator, a breathing machine that blows air into your lungs. It also carries carbon dioxide out of your lungs. Other breathing treatments, such as noninvasive positive pressure ventilation (NPPV), which uses mild air pressure to keep your airways open while you sleep. Another treatment is a special bed that rocks back and forth, to help you breathe in and out. Fluids, often through an intravenous (IV), to improve blood flow throughout your body. They also provide nutrition. Medicines for discomfort Treatments for the cause of the respiratory failure. These treatments may include medicines and procedures. If you have respiratory failure, see your health care provider for ongoing medical care. Your provider may suggest pulmonary rehabilitation. If your respiratory failure is chronic, make sure that you know when and where to get help for your symptoms. You need emergency care if you have severe symptoms, such as trouble catching your breath or talking. You should call your provider if you notice that your symptoms are worsening or if you have new signs and symptoms. Living with respiratory failure may cause fear, anxiety, depression, and stress. Talk therapy, medicines, and support groups can help you feel better. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary: Respiratory Failure, also known as acute respiratory failure, is related to neonatal respiratory failure and adult respiratory distress syndrome, and has symptoms including hemoptysis, dyspnea and apnea. An important gene associated with Respiratory Failure is CHAT (Choline O-Acetyltransferase), and among its related pathways/superpathways are Diseases of glycosylation and Surfactant metabolism. The drugs Amiodarone and Digoxin have been mentioned in the context of this disorder. Affiliated tissues include lung, spinal cord and heart, and related phenotypes are homeostasis/metabolism and growth/size/body region

PubMed Health : 63 Respiratory failure: Respiratory (RES-pih-rah-tor-e) failure is a condition in which not enough oxygen passes from your lungs into your blood. Your body's organs, such as your heart and brain, need oxygen-rich blood to work well. Respiratory failure also can occur if your lungs can't properly remove carbon dioxide (a waste gas) from your blood. Too much carbon dioxide in your blood can harm your body's organs. Both of these problems—a low oxygen level and a high carbon dioxide level in the blood—can occur at the same time. Diseases and conditions that affect your breathing can cause respiratory failure. Examples include COPD (chronic obstructive pulmonary disease) and spinal cord injuries. COPD prevents enough air from flowing in and out of the airways. Spinal cord injuries can damage the nerves that control breathing.

Disease Ontology: 11 A lung disease characterized by inadequate gas exchange by the respiratory system.

Wikipedia: 75 Respiratory failure results from inadequate gas exchange by the respiratory system, meaning that the... more...

Related Diseases for Respiratory Failure

Diseases in the Respiratory Failure family:

Severe Acute Respiratory Syndrome

Diseases related to Respiratory Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1888)
# Related Disease Score Top Affiliating Genes
1 neonatal respiratory failure 33.4 SFTPD SFTPC SFTPB SCGB1A1 NKX2-1 ABCA3
2 adult respiratory distress syndrome 32.9 SFTPD SFTPC SFTPB SCGB1A1
3 lung disease 32.7 SFTPD SFTPC SFTPB SCGB1A1 NKX2-1 ABCA3
4 pneumonia 32.6 SFTPD SFTPC SFTPB SCGB1A1 PIK3C2A
5 pulmonary alveolar microlithiasis 32.5 SFTPD SFTPB ABCA3
6 newborn respiratory distress syndrome 32.4 TTN SFTPD SFTPC SFTPB NKX2-1 ABCA3
7 myasthenia gravis 32.4 TTN RYR1 MUSK
8 interstitial lung disease 2 32.3 SFTPD SFTPC SFTPB SCGB1A1 ABCA3
9 acute interstitial pneumonia 32.3 SFTPD SFTPC
10 surfactant dysfunction 32.3 SFTPC SFTPB ABCA3
11 rigid spine muscular dystrophy 1 32.3 TTN SELENON RYR1 GAA
12 hereditary pulmonary alveolar proteinosis 32.2 SFTPC SFTPB ABCA3
13 myofibrillar myopathy 32.2 TTN SELENON RYR1
14 myopathy, centronuclear, 1 32.1 TTN SELENON RYR1
15 neuromuscular disease 32.1 TTN SELENON RYR1 MUSK IGHMBP2 GAA
17 myopathy, areflexia, respiratory distress, and dysphagia, early-onset 32.0 SELENON IGHMBP2
18 interstitial lung disease 31.9 SFTPD SFTPC SFTPB NKX2-1 INPP5E ABCA3
19 diaphragmatic hernia, congenital 31.8 SFTPC SFTPB NKX2-1 ABCA3
20 meconium aspiration syndrome 31.8 TTN SFTPB SCGB1A1 ABCA3
21 muscular dystrophy 31.7 TTN SELENON RYR1 PIK3C2A GAA
22 muscular atrophy 31.4 TTN RYR1 IGHMBP2 DCTN1
23 pulmonary alveolar proteinosis 31.3 SFTPD SFTPC SFTPB
24 myotonic dystrophy 1 31.3 TTN RYR1 PIK3C2A GAA
25 respiratory distress syndrome in premature infants 31.3 SFTPC SFTPB ABCA3
26 ptosis 31.3 TTN RYR1 MUSK IGHMBP2 CHAT
27 batten-turner congenital myopathy 31.1 TTN SELENON RYR1 GAA
28 cryptogenic organizing pneumonia 31.1 SFTPD SFTPC
29 patent ductus arteriosus 1 31.1 TTN SFTPB INPP5E
30 lung cancer susceptibility 3 31.1 SFTPD SFTPC SFTPB SCGB1A1 NKX2-1
31 peripheral nervous system disease 31.1 TTN RYR1 MUSK IGHMBP2 CHAT
32 myositis 31.0 TTN RYR1 PIK3C2A
33 congenital myasthenic syndrome 31.0 TTN SELENON RYR1 MUSK IGHMBP2 CHAT
34 idiopathic interstitial pneumonia 31.0 SFTPD SFTPC SFTPB ABCA3
35 thymoma 31.0 TTN RYR1 NKX2-1
36 limb-girdle muscular dystrophy 30.9 TTN RYR1 PIK3C2A GAA
37 pulmonary interstitial emphysema 30.9 TTN SFTPD SFTPC SFTPB ABCA3
38 patent foramen ovale 30.9 TTN PIK3C2A NKX2-1
39 lipid pneumonia 30.9 SFTPC SFTPB ABCA3
40 multiminicore disease 30.8 TTN SELENON RYR1
41 pulmonary immaturity 30.8 SFTPD SFTPC SFTPB ABCA3
42 interstitial pneumonitis, desquamative, familial 30.7 SFTPD SFTPC SFTPB ABCA3
43 pulmonary hemosiderosis 30.6 SFTPC SFTPB ABCA3
44 distal arthrogryposis 30.6 TTN SELENON RYR1 MUSK IGHMBP2
45 minicore myopathy with external ophthalmoplegia 30.6 TTN RYR1
46 congenital fiber-type disproportion 30.6 TTN SELENON RYR1
47 miyoshi muscular dystrophy 30.5 TTN PIK3C2A GAA
48 myopathy, congenital, bailey-bloch 30.5 SELENON RYR1
49 central core disease of muscle 30.4 SELENON RYR1 GAA
50 muscular disease 30.4 TTN RYR1 PIK3C2A

Comorbidity relations with Respiratory Failure via Phenotypic Disease Network (PDN): (show top 50) (show all 115)

Acquired Polycythemia Acquired Thrombocytopenia
Active Peptic Ulcer Disease Acute Cor Pulmonale
Acute Cystitis Acute Kidney Failure
Acute Myocardial Infarction Acute Pancreatitis
Acute Vascular Insufficiency of Intestine Alcohol Use Disorder
Alcoholic Cardiomyopathy Alcoholic Liver Cirrhosis
Anthracosis Anxiety
Aortic Aneurysm Aortic Valve Disease 1
Asbestosis Aspergillosis
Asthma Bleeding Disorder, Platelet-Type, 11
Bronchiectasis Bronchitis
Bronchopneumonia Candidiasis
Cardiac Arrest Cardiogenic Shock
Chronic Kidney Disease Chronic Pulmonary Heart Disease
Conjunctivitis Conn's Syndrome
Decubitus Ulcer Deficiency Anemia
Dermatomycosis Diabetic Polyneuropathy
Diaphragm Disease Disseminated Intravascular Coagulation
Dysthymic Disorder Encephalopathy
Esophageal Candidiasis Esophagitis
Familial Atrial Fibrillation Generalized Atherosclerosis
Goodpasture Syndrome Granulomatosis with Polyangiitis
Guillain-Barre Syndrome, Familial Heart Disease
Hepatic Encephalopathy Hypertension, Essential
Hypertensive Encephalopathy Hypertrophic Cardiomyopathy

Graphical network of the top 20 diseases related to Respiratory Failure:

Diseases related to Respiratory Failure

Symptoms & Phenotypes for Respiratory Failure

UMLS symptoms related to Respiratory Failure:

hemoptysis; dyspnea; apnea; respiratory distress; cyanosis; stridor; edema; wheezing; inspiratory stridor; rhinorrhea; snoring; sore throat; cheyne-stokes respiration; coughing; hoarseness; sneezing; expiratory wheeze; labored breathing; inspiratory wheeze; choking sensation; pathological conditions, signs and symptoms; signs and symptoms of ill-defined conditions; anoxemia; pleuritic pain; sinus congestion; other symptoms involving respiratory system and chest; bronchorrhea; neonatal cyanosis; gasping for breath; symptoms involving respiratory system and other chest symptoms; nasal congestion (finding); nasal irritation; neck tightness; larynx pain

MGI Mouse Phenotypes related to Respiratory Failure:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.43 ABCA3 CHAT DCTN1 GAA IGHMBP2 INPP5E
2 growth/size/body region MP:0005378 10.28 CHAT GAA IGHMBP2 INPP5E MUSK NKX2-1
3 cellular MP:0005384 10.21 DCTN1 GAA IGHMBP2 INPP5E MUSK NKX2-1
4 muscle MP:0005369 10.11 CHAT DCTN1 GAA IGHMBP2 MUSK RYR1
5 cardiovascular system MP:0005385 10.1 ABCA3 CHAT GAA IGHMBP2 INPP5E NKX2-1
6 behavior/neurological MP:0005386 10.1 ABCA3 CHAT DCTN1 GAA IGHMBP2 MUSK
7 respiratory system MP:0005388 9.93 ABCA3 CHAT IGHMBP2 MUSK NKX2-1 RYR1
8 skeleton MP:0005390 9.65 CHAT GAA IGHMBP2 INPP5E MUSK NKX2-1
9 mortality/aging MP:0010768 9.58 ABCA3 CHAT DCTN1 IGHMBP2 INPP5E MUSK

Drugs & Therapeutics for Respiratory Failure

PubMed Health treatment related to Respiratory Failure: 63

Treatment for respiratory failure depends on whether the condition is acute (short-term) or chronic (ongoing) and its severity. Treatment also depends on the condition's underlying cause. Acute respiratory failure can be a medical emergency. It often is treated in an intensive care unit at a hospital. Chronic respiratory failure often can be treated at home. If chronic respiratory failure is severe, your doctor may recommend treatment in a long-term care center. One of the main goals of treating respiratory failure is to get oxygen to your lungs and other organs and remove carbon dioxide from your body. Another goal is to treat the underlying cause of the condition.

Drugs for Respiratory Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 492)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
Digoxin Approved Phase 4 20830-75-5 3062 2724385 30322
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
Losartan Approved Phase 4 114798-26-4 3961
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
Sargramostim Approved, Investigational Phase 4 123774-72-1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Acetazolamide Approved, Vet_approved Phase 4 59-66-5, 1424-27-7 1986
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
Adenosine Approved, Investigational Phase 4 58-61-7 60961
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6 9578005
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
Atropine Approved, Vet_approved Phase 4 101-31-5, 5908-99-6, 51-55-8 3661 154417 174174
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
Diclofenac Approved, Vet_approved Phase 4 15307-86-5, 15307-79-6 3033
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
Metamizole Approved, Investigational, Withdrawn Phase 4 50567-35-6 3111 522325
Orphenadrine Approved Phase 4 83-98-7 4601
Nalbuphine Approved Phase 4 20594-83-6 5311304
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
Eprosartan Approved Phase 4 133040-01-4 5281037
Candesartan cilexetil Approved Phase 4 145040-37-5
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 158781 130881
Omalizumab Approved, Investigational Phase 4 242138-07-4
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
Etomidate Approved Phase 4 33125-97-2 667484
Rivaroxaban Approved Phase 4 366789-02-8 9875401
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
Nintedanib Approved Phase 4 656247-17-5 135423438 9809715
Infliximab Approved Phase 4 170277-31-3
33 Poractant alfa Approved Phase 4 129069-19-8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
Butorphanol Approved, Illicit, Vet_approved Phase 4 58786-99-5, 42408-82-2 5361092
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
Lacosamide Approved Phase 4 175481-36-4 21634109 219078
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
Remifentanil Approved Phase 4 132875-61-7 60815
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456 5824
Succinylcholine Approved Phase 4 306-40-1, 71-27-2 5314
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875

Interventional clinical trials:

(show top 50) (show all 1914)
# Name Status NCT ID Phase Drugs
1 Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial Unknown status NCT04334629 Phase 4 Ibuprofen
2 A Multicentre, Randomized, Clinical Trial of Noninvasive Ventilation: Neurally Adjusted Ventilatory Assist (NAVA) vs. Pressure Support in Pediatric Acute Respiratory Failure - NINAVAPed Protocol Unknown status NCT01873521 Phase 4
3 A Pilot Study: Comparing Physiological Parameters and Outcome Variables Using Pressure Support Ventilation Versus Pressure Controlled Ventilation in Patients With Chronic Respiratory Failure Unknown status NCT00994552 Phase 4
4 Non-Invasive Positive Pressure Mask Ventilation vs Extrathoracic Biphasic Cuirass Ventilation in Patients With Acute Respiratory Failure: A Randomized Prospective Study. Unknown status NCT00331656 Phase 4
5 Randomized Controlled Trial of Inspiratory Muscle Training in Patients With Stable Hypercapnic Respiratory Failure Due to COPD Unknown status NCT00291460 Phase 4
6 Functional Residual Capacity Guided Alveolar Recruitment Strategy in Patients With Acute Respiratory Failure After Cardiac Surgery Unknown status NCT01280019 Phase 4
7 Rapid Atrial Fibrillation Treatment Strategy Unknown status NCT04092621 Phase 4 Amiodarone in Parenteral Dosage Form;Amiodarone Pill;Rate-control therapy
8 A Randomized Controlled Trial Comparing SGC and Conventional Empiric Treatment for Glucose Control in Critically Ill Patients With Mechanical Ventilation in ICU Unknown status NCT02491346 Phase 4
9 Role of Non-invasive Ventilation in Amyotrophic Lateral Sclerosis: Volume Versus Pressure Mode Unknown status NCT00560287 Phase 4
10 Home Non Invasive Ventilation (NIV) Treatment for COPD-patients After a NIV-treated Exacerbation Unknown status NCT01513655 Phase 4
11 Partial Neuromuscular Blockade to Facilitate Lung and Diaphragm Protective Mechanical Ventilation in Intensive Care Unit Patients: a Randomized Controlled Pilot Study Unknown status NCT03646266 Phase 4 Rocuronium Bromide
12 The Effect of Immunonutrition on Outcome and Postoperative Recovery in Patients Undergoing Elective Surgical Repair of a Thoraco (Abdominal) Aneurysm Aorta Unknown status NCT00339053 Phase 4 Immunonutrition ( Impact)
13 Phase 4, Single Centre, Single Blinded,Prospective Randomised Cross Over Comparison on the Physiological Response of Post Extubation Intensive Care Patients to Non-invasive Ventilation Using Either Air O2 or Heliox21 Unknown status NCT01498432 Phase 4 Heliox21;Air O2
14 Normal Oxygenation Maintenance in Intensive Care Unit: Randomized Controlled Trial Unknown status NCT01319643 Phase 4 Oxygen
15 Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion Unknown status NCT01353105 Phase 4
16 CPAP Application at Delivery Room at Very Low Birth Weight Infants Unknown status NCT01024361 Phase 4
17 Randomized Open Label Study of Standard of Care Plus an Angiotensin II Receptor Blocker Compared to Standard of Care Alone to Minimize the Progression to Respiratory Failure in SARS-CoV-2 Infection Completed NCT04340557 Phase 4 Losartan
18 A Randomized Trial to Compare the Effectiveness of Hospital or Ambulatory Approach for Adaptation to Non-Invasive Mechanical Ventilation in Patients With Chronic Respiratory Failure Secondary to Neuromuscular Diseases or Thoracic Cage Alterations Completed NCT00698958 Phase 4
19 A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure. Completed NCT04326920 Phase 4 Sargramostim
20 A Randomized Controlled Trial Comparing Two Protocols to Withdraw Non-invasive Ventilation (NIV) After an Episode of Hypercapnic Respiratory Failure Completed NCT00775710 Phase 4
21 Multicenter, Randomised Study of the Use of Non-Invasive Ventilation (NIV) Versus Oxygen Therapy (O2) in Reducing Dyspnea in End-stage Solid Cancer Patients With Respiratory Failure and Distress Completed NCT00533143 Phase 4
22 Efficacy of Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19 Completed NCT04726098 Phase 4 Dexamethasone high dose;Dexamethasone low dose
23 Early Application of CPAP in Hematologic Neutropenic Patients Avoid Acute Respiratory Failure Completed NCT00507533 Phase 4
24 Handling Oxygenation Targets in Adults With Acute Hypoxaemic Respiratory Failure in the Intensive Care Unit: A Randomised Clinical Trial of a Lower Versus a Higher Oxygenation Target Completed NCT03174002 Phase 4 Oxygen
25 Hypercapnic Acute Respiratory Failure: Is the Helmet an Effective Interface?" Completed NCT01645358 Phase 4
26 Effect of High-dose L-Carnitine Supplementation on Diaphragmatic Function Assessed by Ultrasonography in Critically Ill Patients With Respiratory Failure: a Randomized Clinical Trial Completed NCT05322447 Phase 4 L Carnitine ( low dose);L-Carnitine ( high dose)
27 Acetazolamide for Respiratory Failure in Combination With Metabolic Alkalosis Completed NCT00222534 Phase 4 Acetazolamide;Placebo
28 Inhaled Nitric Oxide in Neonates With Elevated A-aDO2 Gradients Not Requiring Mechanical Ventilation Completed NCT00732537 Phase 4 inhaled Nitric Oxide;Oxygen (>90% by hood) - standard therapy
29 The Study of Pharmacokinetics and Pharmacodynamics of a Loading Dose Cisatracurium in Critically Ill Patients Completed NCT03337373 Phase 4 cisatracurium
30 Assessment of the Cerebral Tissue Oxygenation and the Bioelectrical Brain Activity of Preterm Newborns During Administration of Two Different Surfactant Completed NCT01941524 Phase 4 Poractant alfa instillation;Beractant instillation
31 Preventing Cardiovascular collaPse With Administration of Fluid Resuscitation Before Endotracheal Intubation: The PrePARE Trial Completed NCT03026777 Phase 4 intravenous crystalloid fluid, 500 mL
32 Phase IV Study of Comparison of the Efficacy for Stress Ulcer Prophylaxis Between the Patients Received Lansoprazole OD and Control Group Weaning From Mechanical Ventilator in Respiratory Care Center: a Randomized Control Trial Completed NCT00708149 Phase 4 lansoprazole OD;placebo
33 Preventing Cardiovascular Collapse With Administration of Fluid Resuscitation During Induction and Intubation (PREPARE II Trial) Completed NCT03787732 Phase 4 Fluid Bolus
34 Prevention of Pressure Ulcers in Patients Under Non-Invasive Mechanical Ventilation. Randomized Clinical Trial Completed NCT02526862 Phase 4
35 Patients-ventilator Interaction During Sleep: the Role of Humidification. A Pilot Short Term Study Completed NCT01038791 Phase 4
36 Short Term Physiological Effects of Nasal High Oxygen Flow vs Low Oxygen Flow and Noninvasive Ventilation (NIV) on Respiratory Mechanics Completed NCT02363920 Phase 4
37 Checklists and Upright Positioning in Endotracheal Intubation of Critically Ill Patients (Check-UP) Trial Completed NCT02497729 Phase 4
38 Chronic Obstructive Pulmonary Disease and Weaning From Mechanical Ventilation in Difficult to Wean Patients; Randomized Prospective Study Completed NCT00355732 Phase 4
39 Non-Positive Pressure Ventilation in Hypoxemic Patients. A Randomized Study Completed NCT00925860 Phase 4
40 High-assistance Proportional Assist Ventilation (PAV) vs. Assist-Control Ventilation (ACV) in Early Stage of Critically Ill Patients Completed NCT01204281 Phase 4
41 Effect of a Closed Loop Ventilation Strategy on Reducing the Total Duration of Mechanical Ventilation of Intubated Intensive Care Unit Patients: A Randomized Controlled Trial Completed NCT01472302 Phase 4
42 PRO-DEFENSE: Propofol Versus Dexmedetomidine for Sedation in Mechanically Ventilated Patients With Sepsis Completed NCT02203019 Phase 4 Propofol;Dexmedetomidine;Fentanyl
43 Effects of Remifentanil on Breathing Pattern, Respiratory Effort and Gas Exchange in Mechanically Ventilated Patients. Completed NCT00665119 Phase 4 remifentanil;placebo
44 Effect of Non-invasive Ventilation (NIV) on Cerebral Oxygenation Completed NCT02454582 Phase 4
45 Does a Diagnostic Strategy Reduce Duration and Cost of Hospitalization in Patients With Acute Dyspnea? BASEL II Intensive Care Unit Completed NCT00130559 Phase 4
46 Effect of Neuromuscular Blockade and Reversal by Sugammadex Versus Neostigmine on Breathing When Hypoxic or Hypercapnic in Volunteers Completed NCT02845375 Phase 4 Sugammadex;Neostigmine;Placebo
47 Diclofenac Premedication, as the Effect of Preemptive Analgesia After Post-thoracotomy Chest and Shoulder Pain, as Well as the Changes of the Postoperative Breathing Function Values, a Randomized, Controlled, Prospective Trial Completed NCT02445599 Phase 4 Diclofenac;Midazolam;Atropine;bucain + fentanyl;Nalbuphine;Metamizole-sodium;Tramadol
48 Interscalene Block on Ventilatory Function After Shoulder Surgery : Evaluation of Single or Continuous Injection Completed NCT01740453 Phase 4 ropivacaine 2 mg/ml
49 The NAPRESSIM Trial. The Use of Low Dose Prophylactic Naloxone Infusion to Prevent Respiratory Depression With Intrathecal Morphine. Completed NCT02885948 Phase 4 Naloxone;Placebo
50 Effect of Intraperitoneal and Intravenous Lignocaine on Pain Relief Following Laparoscopic Cholecystectomy - A Randomized Clinical Trial Completed NCT01717222 Phase 4 Intraperitoneal Lignocaine;Intravenous Lignocaine

Search NIH Clinical Center for Respiratory Failure

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Nalmefene hydrochloride
Naloxone Hydrochloride
prednisolone acetate
Prednisolone sodium phosphate
prednisolone tebutate

Genetic Tests for Respiratory Failure

Genetic tests related to Respiratory Failure:

# Genetic test Affiliating Genes
1 Respiratory Insufficiency 28
2 Respiratory Failure 28

Anatomical Context for Respiratory Failure

Organs/tissues related to Respiratory Failure:

MalaCards : Lung, Spinal Cord, Heart, Brain, Skin, Liver, Bone Marrow

Publications for Respiratory Failure

Articles related to Respiratory Failure:

(show top 50) (show all 60287)
# Title Authors PMID Year
Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial. 62 41
36418984 2022
Application of improved Glasgow coma scale score as switching point for sequential invasive-noninvasive mechanical ventilation on chronic obstructive pulmonary disease (COPD) with respiratory failure. 62 41
36401492 2022
Starting HMV at home: a reasonable option for many patients? 41
36352387 2022
Association of the CCR3 gene polymorphism with aspirin exacerbated respiratory disease. 53 62
20022477 2010
Lack of correlation between pulmonary disease and cystic fibrosis transmembrane conductance regulator dysfunction in cystic fibrosis: a case report. 53 62
20420703 2010
Serum eosinophilic cationic protein: is there a role in respiratory disorders? 53 62
20170318 2010
Pulmonary cyclooxygenase-1 (COX-1) and COX-2 cellular expression and distribution after respiratory syncytial virus and parainfluenza virus infection. 53 62
20121401 2010
Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. 53 62
19824815 2010
Inherited surfactant deficiency caused by uniparental disomy of rare mutations in the surfactant protein-B and ATP binding cassette, subfamily a, member 3 genes. 53 62
19647838 2009
Genetics and pharmacogenetics of the leukotriene pathway. 53 62
19665766 2009
Several interleukin-4 and interleukin-13 gene single nucleotide polymorphisms among Chinese asthmatic patients. 53 62
19772762 2009
Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model. 53 62
19539245 2009
Interfamilial phenotypic heterogeneity in SMARD1. 53 62
19157874 2009
Association of polymorphisms in the human surfactant protein-D (SFTPD) gene and postnatal pulmonary adaptation in the preterm infant. 53 62
18785967 2009
[Lung diseases associated with inherited disorders of surfactant metabolism]. 53 62
18804975 2008
IL-13 as a therapeutic target for respiratory disease. 53 62
18502398 2008
Surfactant protein B deficiency caused by a novel mutation involving multiple exons of the SP-B gene. 53 62
18558554 2008
Clinical and mutational profile in spinal muscular atrophy with respiratory distress (SMARD): defining novel phenotypes through hierarchical cluster analysis. 53 62
17431882 2007
IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. 53 62
17379289 2007
Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. 53 62
17021257 2007
Efficacy of IL-13 neutralization in a sheep model of experimental asthma. 53 62
17023688 2007
Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors. 53 62
17245350 2007
Adult glycogenosis type II (Pompe's disease): morphological abnormalities in muscle and skin biopsies compared with acid alpha-glucosidase activity. 53 62
18176891 2007
Lung specific developmental expression of the Xenopus laevis surfactant protein C and B genes. 53 62
16798105 2007
Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast. 53 62
17155857 2007
Predicting patients at high-risk of systemic reactions to cluster allergen immunotherapy: a pilot prospective observational study. 53 62
18088021 2007
Microsomal epoxide hydrolase is not associated with COPD in a community-based sample. 53 62
17564249 2006
Inherited surfactant protein-B deficiency and surfactant protein-C associated disease: clinical features and evaluation. 53 62
17142157 2006
Relationship between extremely low total serum IgE levels and rhinosinusitis. 53 62
17165274 2006
Mitochondrial oxidative stress in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. 53 62
16763223 2006
Long-term outcomes after infant lung transplantation for surfactant protein B deficiency related to other causes of respiratory failure. 53 62
17011330 2006
Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory disease. 53 62
16916276 2006
Acute rhabdomyolysis complicating status asthmaticus in children: case series and review. 53 62
16912630 2006
Are phosphodiesterase 4 inhibitors just more theophylline? 53 62
16750981 2006
Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. 53 62
16323216 2006
Screening for allergic respiratory disease in the general population with the ADVIA Centaur Allergy Screen Assay. 53 62
16436144 2006
Surfactant protein B deficiency: a rare cause of respiratory failure in a Lebanese newborn. 53 62
16521884 2006
Reversibility of lung inflammation caused by SP-B deficiency. 53 62
16024721 2005
Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. 53 62
16005263 2005
Role of immunoglobulin E sensitization in eczema, previously referred to as atopic dermatitis. 53 62
20476939 2005
Interstitial lung disease in children -- genetic background and associated phenotypes. 53 62
15819986 2005
[Neonatal respiratory failure associated with mutation in the surfactant protein C gene]. 53 62
15737281 2005
Simian human immunodeficiency virus-associated pneumonia correlates with increased expression of MCP-1, CXCL10, and viral RNA in the lungs of rhesus macaques. 53 62
15681820 2005
Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. 53 62
15639117 2005
Nicoletella semolina gen. nov., sp. nov., a new member of Pasteurellaceae isolated from horses with airway disease. 53 62
15583279 2004
Actin mutations are one cause of congenital fibre type disproportion. 53 62
15468086 2004
C-reactive protein and body mass index predict outcome in end-stage respiratory failure. 53 62
15302742 2004
Aspirin and NSAID sensitivity. 53 62
15242723 2004
[Surfactant-associated proteins B and C: molecular biology and physiologic properties]. 53 62
15229816 2004
Association between surfactant protein B + 1580 polymorphism and the risk of respiratory failure in adults with community-acquired pneumonia. 53 62
15190959 2004

Variations for Respiratory Failure

ClinVar genetic disease variations for Respiratory Failure:

5 (show all 19)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TAMM41 NM_001284401.2(TAMM41):c.329A>G (p.Tyr110Cys) SNV Pathogenic
1299473 GRCh37: 3:11880778-11880778
GRCh38: 3:11839304-11839304
2 TAMM41 NM_001284401.2(TAMM41):c.806dup (p.Asn269fs) DUP Pathogenic
1299474 GRCh37: 3:11851058-11851059
GRCh38: 3:11809584-11809585
3 CHAT NM_020549.5(CHAT):c.2081C>G (p.Ser694Cys) SNV Pathogenic
523529 rs201439531 GRCh37: 10:50872926-50872926
GRCh38: 10:49664880-49664880
4 CHAT NM_020549.5(CHAT):c.1061C>T (p.Thr354Met) SNV Pathogenic
523528 rs769234940 GRCh37: 10:50835781-50835781
GRCh38: 10:49627735-49627735
5 INPP5E NM_019892.6(INPP5E):c.1132C>T (p.Arg378Cys) SNV Pathogenic
400 rs121918130 GRCh37: 9:139327634-139327634
GRCh38: 9:136433182-136433182
6 PMS2 NM_000535.7(PMS2):c.1927C>T (p.Gln643Ter) SNV Pathogenic
91320 rs63751422 GRCh37: 7:6026469-6026469
GRCh38: 7:5986838-5986838
7 MUSK NM_005592.4(MUSK):c.1724T>C (p.Ile575Thr) SNV Likely Pathogenic
190467 rs751889864 GRCh37: 9:113547944-113547944
GRCh38: 9:110785664-110785664
8 MUSK NM_005592.4(MUSK):c.2365G>A (p.Gly789Ser) SNV Likely Pathogenic
374195 rs1057518966 GRCh37: 9:113563023-113563023
GRCh38: 9:110800743-110800743
9 TP73 NM_005427.4(TP73):c.613G>T (p.Glu205Ter) SNV Likely Pathogenic
1192322 GRCh37: 1:3638768-3638768
GRCh38: 1:3722204-3722204
10 ABCA3 NM_001089.3(ABCA3):c.875A>T (p.Glu292Val) SNV Likely Pathogenic
203381 rs149989682 GRCh37: 16:2367764-2367764
GRCh38: 16:2317763-2317763
11 RYR1 NM_000540.3(RYR1):c.1186G>A (p.Glu396Lys) SNV Likely Pathogenic
374199 rs774919231 GRCh37: 19:38942467-38942467
GRCh38: 19:38451827-38451827
12 RYR1 NM_000540.3(RYR1):c.844C>T (p.Arg282Trp) SNV Likely Pathogenic
374200 rs1057518970 GRCh37: 19:38939038-38939038
GRCh38: 19:38448398-38448398
13 ERF NM_006494.4(ERF):c.1636C>T (p.Arg546Ter) SNV Uncertain Significance
599007 rs764412749 GRCh37: 19:42752628-42752628
GRCh38: 19:42248476-42248476
14 GATA4 NM_001308093.3(GATA4):c.94G>C (p.Ala32Pro) SNV Uncertain Significance
599008 rs773545065 GRCh37: 8:11565915-11565915
GRCh38: 8:11708406-11708406
15 ABCA3 NM_001089.3(ABCA3):c.1336G>A (p.Asp446Asn) SNV Uncertain Significance
318546 rs200803298 GRCh37: 16:2354101-2354101
GRCh38: 16:2304100-2304100
16 ITGA3 NM_002204.4(ITGA3):c.1766G>C (p.Arg589Pro) SNV Uncertain Significance
1339481 GRCh37: 17:48153781-48153781
GRCh38: 17:50076417-50076417
17 COPA NM_004371.4(COPA):c.154+6A>G SNV Uncertain Significance
1676272 GRCh37: 1:160309965-160309965
GRCh38: 1:160340175-160340175
18 TNFRSF13B NM_012452.3(TNFRSF13B):c.310T>C (p.Cys104Arg) SNV Uncertain Significance
5302 rs34557412 GRCh37: 17:16852187-16852187
GRCh38: 17:16948873-16948873
19 VANGL1 NM_138959.3(VANGL1):c.523C>T (p.Arg175Trp) SNV Uncertain Significance
167818 rs142594314 GRCh37: 1:116206600-116206600
GRCh38: 1:115663979-115663979

Expression for Respiratory Failure

Search GEO for disease gene expression data for Respiratory Failure.

GO Terms for Respiratory Failure

Cellular components related to Respiratory Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 clathrin-coated endocytic vesicle GO:0045334 9.63 SFTPD SFTPC SFTPB
2 multivesicular body lumen GO:0097486 9.56 SFTPC SFTPB
3 lamellar body GO:0042599 9.43 SFTPC SFTPB ABCA3
4 alveolar lamellar body GO:0097208 9.1 SFTPC SFTPB ABCA3

Biological processes related to Respiratory Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to caffeine GO:0071313 9.26 SELENON RYR1
2 respiratory gaseous exchange by respiratory system GO:0007585 9.1 SFTPD SFTPC SFTPB

Sources for Respiratory Failure

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....